Cytocom (CBLI) Stock Analysis

What Cytocom does

Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.

Key metrics

ETFs linked to CBLI

Broad-market and Healthcare sector ETFs an investor holding Cytocom is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CBLI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cytocom?

Cytocom trades under the ticker CBLI on NASDAQ.

Which exchange is CBLI listed on?

CBLI is listed on NASDAQ.

What sector does Cytocom operate in?

Cytocom is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CBLI in a portfolio?

PortView shows CBLI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.